Loreto Quesada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Loreto Quesada has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Isabel Gomila
Clinical Analysis Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain
3 shared publications - Bernardino Barceló
Inst Invest Sanitaria Islas Baleares IdISBa, Grp Invest Toxicol Clin, Palma De Mallorca, Spain
2 shared publications Albert Torrents
Reference Laboratory, Barcelona, Spain
1 shared publication- Elena Miravet
Division of Neurology, Department of Paediatrics, Hospital Universitari Son Espases, Palma de Mallorca, Spain
1 shared publication Jordi Puiguriguer Ferrando
Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Baleares, España; Unidad de Toxicología Clínica, Servicio de Urgencias Médicas, Hospital Universitario Son Espases, Palma de Mallorca, Baleares, España
1 shared publicationJulia Fernández
Department of Rheumatology, Hospital Universitari Son Espases, Palma de Mallorca, Spain
1 shared publication
Latest Publications
- 1 April 2017
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 39 (2) , 192-196
Cross-Reactivity of Chloroquine and Hydroxychloroquine With DRI Amphetamine Immunoassay
Chloroquine and hydroxychloroquine are medical drugs used to treat the chemoprophylaxis of malaria and a second-line anti-inflammatory drug. We performed a study of cross-reactivity of chloroquine and hydroxychloroquine in the DRI Amphetamine Assay inspired by a case report of a self-ingestion of chloroquine after a family dispute, that involved the following: (1) an in vitro study with control samples of healthy subjects, (2) an in vivo study with samples of patients with rheumatoid arthritis, and (3) an evaluation of the cross-reactivity of chloroquine and hydroxychloroquine in 3 additional immunoassays. In the case report, the Amphetamine DRI assay resulted positive both at 1000 ng/mL cutoff (1507 and 1137 ng/mL) and at 500 ng/mL cutoff (1178 and 642 ng/mL). Chloroquine urine levels were 103,900 and 100,900 ng/mL at 5 and 9 hours after ingestion. The results with control samples showed a positive cross-reactivity of chloroquine in the DRI Amphetamine Assay (approximately 0.74% and 0.89% at cutoff of 1000 and 500 ng/mL, respectively). Hydroxychloroquine did not cross-react with the DRI Amphetamine Assay up to 1,000,000 ng/mL. In patients treated with chloroquine or hydroxychloroquine, DRI Amphetamine did not produce false-positive results. The comparative assay study showed a positive cross-reactivity of chloroquine in the Emit II Plus Amphetamines Assay with control samples. Chloroquine can cause false-positive results in the DRI Amphetamine Assay when it is present at high concentrations. Hydroxychloroquine did not produce false-positive results neither in the DRI Amphetamine Assay nor in the others immunoassays evaluated.
- 1 April 2017
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 39 (2) , 192-196
Cross-Reactivity of Chloroquine and Hydroxychloroquine With DRI Amphetamine Immunoassay
Chloroquine and hydroxychloroquine are medical drugs used to treat the chemoprophylaxis of malaria and a second-line anti-inflammatory drug. We performed a study of cross-reactivity of chloroquine and hydroxychloroquine in the DRI Amphetamine Assay inspired by a case report of a self-ingestion of chloroquine after a family dispute, that involved the following: (1) an in vitro study with control samples of healthy subjects, (2) an in vivo study with samples of patients with rheumatoid arthritis, and (3) an evaluation of the cross-reactivity of chloroquine and hydroxychloroquine in 3 additional immunoassays. In the case report, the Amphetamine DRI assay resulted positive both at 1000 ng/mL cutoff (1507 and 1137 ng/mL) and at 500 ng/mL cutoff (1178 and 642 ng/mL). Chloroquine urine levels were 103,900 and 100,900 ng/mL at 5 and 9 hours after ingestion. The results with control samples showed a positive cross-reactivity of chloroquine in the DRI Amphetamine Assay (approximately 0.74% and 0.89% at cutoff of 1000 and 500 ng/mL, respectively). Hydroxychloroquine did not cross-react with the DRI Amphetamine Assay up to 1,000,000 ng/mL. In patients treated with chloroquine or hydroxychloroquine, DRI Amphetamine did not produce false-positive results. The comparative assay study showed a positive cross-reactivity of chloroquine in the Emit II Plus Amphetamines Assay with control samples. Chloroquine can cause false-positive results in the DRI Amphetamine Assay when it is present at high concentrations. Hydroxychloroquine did not produce false-positive results neither in the DRI Amphetamine Assay nor in the others immunoassays evaluated.
- 1 November 2016
- Published by Elsevier in Medicina Clinica
- Vol. 147 (9) , 421
Primera confirmación en España del uso de la burundanga en una sumisión química atendida en urgencias
- 1 November 2016
- Published by Elsevier in Medicina Clinica
- Vol. 147 (9) , 421
Primera confirmación en España del uso de la burundanga en una sumisión química atendida en urgencias
- 1 September 2016
- Published by Elsevier in Forensic Science International
- Vol. 266, e18-e22
Alimemazine poisoning as evidence of Munchausen syndrome by proxy: A pediatric case report
- 1 September 2016
- Published by Elsevier in Forensic Science International
- Vol. 266, e18-e22
Alimemazine poisoning as evidence of Munchausen syndrome by proxy: A pediatric case report